China Biologic Products Holdings Inc operates within the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares China Biologic Products Holdings Inc with three other
companies in this sector in China:
Tonghua Dongbao Medicines Company Limited
sales of 2.54 billion Chinese Renmimbi [US$375.16 million]
of which 89%
Shanghai Raas Blood Products Company Limited
(1.93 billion Chinese Renmimbi [US$284.57 million]
of which 99%
was Blood products production and sales), and
Hualan Biological Engineering Inc
(2.37 billion Chinese Renmimbi [US$349.59 million]
of which 88%
was Blood Product).
During the year ended December of 2017, sales at
China Biologic Products Holdings Inc were 2.49 billion Chinese Renmimbi (US$368.26 million).
increase of 9.9%
versus 2016, when the company's sales were 2.27 billion Chinese Renmimbi.
This was the fifth consecutive year of sales increases at China Biologic Products Holdings Inc
(and since 2012, sales have increased a total of 114%).